Myxoid liposarcoma: it's a hippo's world
Abstract Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a drop‐out RNAi screen to establish hyperactive Yes‐asso...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-04-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201910470 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761516905037824 |
|---|---|
| author | Carla Regina Simone Hettmer |
| author_facet | Carla Regina Simone Hettmer |
| author_sort | Carla Regina |
| collection | DOAJ |
| description | Abstract Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated protein 1 (YAP1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS. These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS. Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP1 expression in MLS, to facilitate treatment decisions and advance therapy. |
| format | Article |
| id | doaj-art-0d15cfd0238d4d53a606cf439bc86840 |
| institution | DOAJ |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2019-04-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-0d15cfd0238d4d53a606cf439bc868402025-08-20T03:06:00ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842019-04-011151310.15252/emmm.201910470Myxoid liposarcoma: it's a hippo's worldCarla Regina0Simone Hettmer1Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of FreiburgDivision of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of FreiburgAbstract Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated protein 1 (YAP1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS. These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS. Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP1 expression in MLS, to facilitate treatment decisions and advance therapy.https://doi.org/10.15252/emmm.201910470 |
| spellingShingle | Carla Regina Simone Hettmer Myxoid liposarcoma: it's a hippo's world EMBO Molecular Medicine |
| title | Myxoid liposarcoma: it's a hippo's world |
| title_full | Myxoid liposarcoma: it's a hippo's world |
| title_fullStr | Myxoid liposarcoma: it's a hippo's world |
| title_full_unstemmed | Myxoid liposarcoma: it's a hippo's world |
| title_short | Myxoid liposarcoma: it's a hippo's world |
| title_sort | myxoid liposarcoma it s a hippo s world |
| url | https://doi.org/10.15252/emmm.201910470 |
| work_keys_str_mv | AT carlaregina myxoidliposarcomaitsahipposworld AT simonehettmer myxoidliposarcomaitsahipposworld |